Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for Maintenance of Weight Loss (SURMOUNT-4)
NCT04660643Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2021
- Primary completion
- Apr 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 3 trial of tirzepatide in obesity, Overweight, sponsored by Eli Lilly and Company. Started Mar 2021; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04660643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660643.